Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00846248 · ClinicalTrials.gov registry record · NA
Chromium and Insulin Resistance
A NA study of Insulin Resistance, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT00846248: Completed NA study of Insulin Resistance, sponsored by University of California, San Francisco.
NCT00846248 is a NA study of Insulin Resistance that has completed, run by University of California, San Francisco. The registered enrollment target is 75 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00846248, a NA study of Insulin Resistance, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
Chromium is an essential nutrient for the maintenance of normal glucose tolerance and its deficiency causes insulin resistance. Chromium administration has also been shown in several studies to lower glucose and insulin levels in patients with type 2 diabetes. Accordingly, we propose to perform a placebo-controlled study of chromium picolinate administration in a cohort of non-obese, non-diabetic, insulin resistant subjects. These subjects will be randomized to 16 weeks of therapy with either 500 mcg twice a day of Chromium or placebo.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT placebo
- DIETARY_SUPPLEMENT Chromium
Study Locations (1)
California
- UCSF - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2006-01 |
| Est. Completion | 2011-07 |
| Phase | NA |
What the finished NCT00846248 record still lists
NCT00846248 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Insulin Resistance appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00846248 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00846248 about?
NCT00846248 is a clinical study titled "Chromium and Insulin Resistance". Chromium is an essential nutrient for the maintenance of normal glucose tolerance and its deficiency causes insulin resistance. Chromium administration has also been shown in several studies to lower glucose and insulin levels in patients with type 2 diabetes. Accordingly, we propose to perform a pl...
What is the current status of trial NCT00846248?
This trial is currently completed. It is a NA study. The enrollment target is 75 participants. The study started on 2006-01. Estimated completion is 2011-07.
What conditions does trial NCT00846248 study?
This clinical trial studies the following conditions: Insulin Resistance.
What interventions are being tested in trial NCT00846248?
The interventions under investigation include: placebo (DIETARY_SUPPLEMENT), Chromium (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00846248?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00846248 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00846248's enrollment target sits among peer trials
75 36th of 120 higher than 85 of 120 other Insulin Resistance trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insulin Resistance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
RECRUITING · NA
-
Small Extracellular Vesicles and Insulin Action
RECRUITING · NA
-
Exercise Effects on Adipose Tissue Structure and Function
RECRUITING · NA
-
New Mechanisms of Obesity
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia